The European Commission announced, on 16 July, that it would not raise any objections to an exemption for sales of medicines made from blood from the Belgian levy on the turnover of pharmaceutical companies. Its investigation showed that the exemption is in line with the logic of the Belgian levy system and therefore does not constitute state aid. A Belgian law, adopted on 14 July 1994, introduced a levy on the pharmaceutical industry based on a percentage of the turnover made on reimbursable medicines.
展开▼
